Amarin to Report First Quarter 2013 Results and Host Conference Call on May 9, 2013

Amarin to Report First Quarter 2013 Results and Host Conference Call on May 9,
2013

BEDMINSTER, N.J. and DUBLIN, May 3, 2013 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, today announced that it will host a conference call with members of
Amarin senior management to discuss the company's first quarter 2013 financial
results and provide an operational update on Thursday, May 9, 2013, at 4:30
p.m. EDT. The conference call will follow the anticipated release of the
company's first quarter 2013 financial results earlier that day.

To participate in the call, please dial 877-407-8033 within the United States
or 201-689-8033 from outside the United States. A replay of the call will be
made available for a period of two weeks following the conference call. To
hear a replay of the call, dial 877-660-6853 (inside the United States) or
201-612-7415 (outside the United States). A replay of the call will also be
available through the company's website shortly after the call. For both
dial-in numbers please use conference ID 411140. The conference call can also
be heard live via the investor relations section of the company's website at
www.amarincorp.com.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA and is available by prescription. For more
information about Vascepa visit www.vascepa.com. For more information about
Amarin visit www.amarincorp.com.

CONTACT: Amarin Contact Information:
         Joseph Bruno
         Director, Investor Relations and Corporate Communications
         Amarin Corporation plc
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.